IMUX logo

IMUX Immunic, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$7.24
-0.28 (-3.72%)

Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other ch…

Market Cap: $98.79Mimux.com

Price

No data yet.

Social Signal Score

45
5d
—
30d
46
5 mentions
—
60d
43
10 mentions
—
90d
45
14 mentions
—
news: 14

Analyst Ratings

12 analysts
Buyconsensus
Strong Buy 0Buy 10Hold 2Sell 0Strong Sell 0
Avg price target$24+231.5%
Low $3Median $24High $45
Current Consensus

Revenue

$0.00
$0.00
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-6.31
$-6.82–$-5.40
8 analysts
FY2026
$-3.75
$-5.66–$-3.06
8 analysts
FY2027
$-2.38
$-4.35–$-1.30
10 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Erik Lundgren
Sector
Healthcare
Industry
Biotechnology
Employees
100
Beta
1.48
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-7.68
imux.com